Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879577 | 0.95 | HTT (0.91) | HTTLMNASMN1; SMN2TGM2FOLH1 | |
| SCHEMBL7820797 | 0.94 | HTT (0.89) | HTTLMNASMN1; SMN2TGM2FOLH1 | |
| SCHEMBL4858734 | 0.94 | HTT (0.88) | HTTLMNASMN1; SMN2TGM2FOLH1 | |
| SCHEMBL3287016 | 0.94 | HTT (0.88) | HTTLMNASMN1; SMN2TGM2FOLH1 | |
| SCHEMBL3694316 | 0.94 | HTT (0.88) | HTTLMNASMN1; SMN2TGM2FOLH1 | |
| SCHEMBL4857273 | 0.94 | HTT (0.88) | HTTLMNASMN1; SMN2TGM2FOLH1 | |
| SCHEMBL2876850 | 0.94 | HTT (0.88) | HTTLMNASMN1; SMN2TGM2FOLH1 | |
| SCHEMBL125577 | 0.94 | HTT (0.88) | HTTLMNASMN1; SMN2TGM2FOLH1 | |
| SCHEMBL2875581 | 0.94 | HTT (0.88) | HTTLMNASMN1; SMN2TGM2FOLH1 | |
| SCHEMBL3693087 | 0.94 | HTT (0.88) | HTTLMNASMN1; SMN2TGM2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716856-A | Method for synthesizing aminoglycoside antibiotic arbekacin | 山东厚德精诚药业有限公司 | 2023-02-28 | — | — | CN | claimed |
| US-7728167-B2 | Process for the preparation of enantiomerically enriched amino acids | DEGUSSA AG (DE) | 2010-06-01 | — | — | US | claimed |
| EP-2123253-A1 | WRINKLING-PREVENTING AND -MODIFYING AGENT | Shiseido Company, Ltd. (JP) | 2009-11-25 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | disclosed |
| WO-2026043829-A1 | CHROMANE CYCLIC AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12521393-B2 | Cytotoxicity targeting chimeras for CCR2-expressing cells | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-13 | — | — | US | disclosed |
| US-20260009029-A1 | COMPOUND FOR INHIBITING EXPRESSION OF LPA GENE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | RIGERNA THERAPEUTICS SUZHOU CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-20260009030-A1 | COMPOUND FOR INHIBITING AGT GENE EXPRESSION, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | RIGERNA THERAPEUTICS SUZHOU CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-4515717-A | INTERMEDIATES FOR 6-UNSUBSTITUTED PENICILLIN ANTIOBIOTICS | CIBA GEIGY CORPORATION (US) | 1985-05-07 | — | — | US | disclosed |
| US-4500457-A | TREATING AN ACYLOXYAZETIDINONE WITH MERCAPTO COMPOUND, GLYOYLIC ESTER, HALOGENATION AGENT, AND PHOSPHINE COMPOUNT THEN CYCLIZATION | CIBA-GEIGY CORPORATION (US) | 1985-02-19 | — | — | US | disclosed |
| US-4476229-A | QUANTITATIVE ANALYSIS OF LIGANDS IN BIOLOGICAL FLUIDS | ABBOTT LABORATORIES (US) | 1984-10-09 | — | — | US | disclosed |
| US-4472379-A | ANTILEUKEMIA AGENTS | SUAMI T (JP) | 1984-09-18 | — | — | US | disclosed |
| EP-0108399-A2 | Substituted carboxyfluoresceins | ABBOTT LABORATORIES (US) | 1984-05-16 | — | — | EP | disclosed |
| US-4447360-A | Intermediates for thia-aza compounds with a β-lactam ring | CIBA-GEIGY CORPORATION (US) | 1984-05-08 | — | — | US | disclosed |
| US-4331676-A | 2-PENEM COMPOUNDS UNSUBSTITUTED IN THE 6 POSITION | CIBA-GEIGY CORPORATION (US) | 1982-05-25 | — | — | US | disclosed |
| US-4221706-A | B-ALANYL OR G-AMINOBUTYRYL-PROLYL-ARGINYL-P-NITROANILIDE, FOR QUANTITATIVE MEASUREMENT OF PROTEOLYTIC ENZYMES | ABBOTT LABORATORIES (US) | 1980-09-09 | — | — | US | disclosed |
| US-4218404-A | HYPOGLYCEMIC AGENTS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | HTT 1768/4885LMNA 2109/4885SMN1; SMN2 1758/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | HTT 2256/4885LMNA 4546/4885SMN1; SMN2 1993/4885 |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | CD4, MALT1, LY6K | HTT 2917/4885LMNA 2507/4885SMN1; SMN2 3725/4885 |
| US-20260009030-A1 | COMPOUND FOR INHIBITING AGT GENE EXPRESSION, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | AGTR1, AGT, AGTR2 | HTT 1981/4885LMNA 488/4885SMN1; SMN2 1612/4885 |
| US-20260009029-A1 | COMPOUND FOR INHIBITING EXPRESSION OF LPA GENE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LPAR6, LPAR2, LPAR1 | HTT 2902/4885LMNA 332/4885SMN1; SMN2 3145/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | HTT 3952/4885LMNA 852/4885SMN1; SMN2 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.